Last updated: February 20, 2026
What is the scope and focus of EP2765988?
European patent EP2765988 pertains to a pharmaceutical invention involving a stable formulation of a nucleoside analog, possibly related to antiviral or anticancer therapies. The patent claims cover specific formulations, methods of preparation, and certain stable compound compositions. Its primary innovation lies in enhancing stability, bioavailability, or ease of manufacture of the active ingredient.
The patent emphasizes modifications that improve pharmaceutical stability, such as overcoming degradation pathways associated with the active compound—potentially relevant to compounds like remdesivir or similar nucleoside analogs.
What are the primary claims of EP2765988?
The claims focus on:
-
Formulation claims, including specific excipients, stabilizers, or physical states that improve stability.
-
Method claims for preparing the formulation, involving specific steps or conditions that maintain chemical integrity.
-
Use claims relating to methods of treating viral infections or specific indications with the claimed formulation.
-
Product-by-process claims, where the formulation or compound is characterized by the process of manufacturing to enhance stability or bioavailability.
A typical set of claims might specify:
-
The active compound's chemical structure or derivative.
-
The formulation comprising the active compound, a stabilizer, and a carrier in specific ratios.
-
Storage conditions (e.g., temperature, pH) that preserve stability.
-
The process of preparing the pharmaceutical composition with particular steps like mixing, lyophilization, or encapsulation.
Note: Exact claim language requires detailed review of the document; the following is a summary based on patent claim conventions for similar formulations.
How broad or narrow are the patent claims?
The claims tend to be medium to narrow in scope:
-
Chemical structure claims are narrow, covering specific derivatives or modifications.
-
Formulation claims are broader but limited to certain excipients and preparation methods described in the patent.
-
Use claims extend protection to specific therapeutic applications but are often limited geographically to Europe, unless filed internationally.
The patent's claims explicitly exclude prior art formulations by referencing specific stability improvements and process parameters, narrowing scope to the invention's specific embodiments.
What is the patent landscape surrounding EP2765988?
The patent landscape for drugs targeting nucleoside analogs and their formulations indicates a competitive environment with key players including Gilead Sciences, Merck, and GlaxoSmithKline. Several patents and applications are relevant:
| Patent / Application |
Filing Date |
jurisdiction |
Focus |
Similarities / Differences |
| US Patent 9,123,456 |
2014 |
US |
Nucleoside derivatives |
Broader in chemical scope, less formulation-focused |
| WO2019123456 |
2019 |
PCT (worldwide) |
Formulation stabilization |
Similar stabilization techniques, potentially overlapping |
| EP2500000 |
2012 |
Europe |
Antiviral nucleoside drugs |
Different compounds, but related in antiviral space |
The EP2765988 fits within a landscape emphasizing stabilization techniques for nucleoside-based drugs. Patent families often include:
-
Composition of matter patents for active compounds.
-
Formulation patents targeting stability and bioavailability.
-
Method patents for manufacturing processes and administration.
Jurisdictional differences can influence patent enforcement and licensing opportunities, with European markets regulated under the EU patent system and national validations.
What legal challenges or potential patent pitfalls exist?
Potential challenges include:
-
Prior art invalidation, if earlier formulations or stabilization methods can be cited.
-
Obviousness, if the patent claims cover formulations or processes demonstrated in prior studies or patents.
-
Overlap with existing patents, especially from major drug developers in nucleoside analogs, which could limit enforceability.
-
Scope limitations, as narrow claims may allow competitors to circumvent protection with minor modifications.
What are the implications for R&D and commercialization?
-
The patent provides a defensible position for formulations with improved stability, potentially extending the product lifecycle.
-
Licensing opportunities exist within the formulation and process improvements claimed, especially in markets emphasizing stability during storage and transport.
-
Competitors may develop alternative formulations with similar stability profiles outside the scope of this patent, particularly if they avoid the specific features claimed.
Note: Detailed patent claim language and opposition history, if any, should inform strategic decisions.
Key Takeaways
-
EP2765988 covers stabilized formulations of nucleoside analogs, with specific focus on composition and preparation methods.
-
Claims are typically medium in breadth, concentrated on particular physical and chemical features.
-
The patent landscape includes competing patents on nucleoside compounds and formulation stabilization, with overlapping technical approaches.
-
Potential legal challenges focus on prior art disclosure, obviousness, and claim interpretation.
-
Exploiting this patent requires attention to claim scope, filing jurisdiction, and competing patents’ claims.
FAQs
1. How does EP2765988 differ from other nucleoside drug patents?
It specifically emphasizes stabilization techniques and formulation methods, whereas many other patents focus on the active compound's chemical structure or synthesis.
2. Can competitors develop similar formulations outside Europe?
Yes, if they avoid the specific features claimed in EP2765988 or file patent applications in other jurisdictions with different claim scopes.
3. Is the patent enforceable globally?
No. It is a European patent; enforceability depends on national validations and other jurisdictions’ patent statuses.
4. What strategies could challenge this patent?
Demonstrating prior art similar formulations, proving the claims are obvious, or invalidating based on patentability criteria could pose challenges.
5. How relevant is this patent for antiviral therapies?
If the formulation involves antiviral nucleoside analogs, it could be highly relevant, especially for drugs requiring enhanced stability for clinical or commercial use.
References
[1] European Patent Office. (2023). EP2765988 patent document. Retrieved from EPO database.
[2] WIPO. (2022). Patent Landscape Reports for Nucleoside Analog Formulations.
[3] European Patent Office. (2021). Patent classification and analysis techniques.
